Effective combinatorial immunotherapy for penile squamous cell carcinoma

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Penile squamous cell carcinoma (PSCC) is a significant health concern, particularly in developing nations.
• The lack of adequate laboratory models hinders research into PSCC's molecular mechanisms and therapeutic strategies.
• Understanding PSCC's biology is crucial for improving patient outcomes.

Purpose of the Study:

• To develop a genetically engineered mouse model for studying penile squamous cell carcinoma (PSCC).
• To investigate the tumor microenvironment and identify therapeutic targets in PSCC.
• To establish a preclinical platform for evaluating novel PSCC treatment strategies.

Main Methods:

• Co-deletion of Smad4 and Apc genes in the androgen-responsive mouse penis epithelium to create a PSCC model.
• Characterization of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs).
• Preclinical evaluation of therapeutic interventions, including immune checkpoint blockade and MDSC-targeting drugs (cabozantinib, celecoxib).
• Investigation of cisplatin chemoresistance mechanisms, particularly in the context of Pten deficiency.

Main Results:

• The developed mouse model successfully recapitulates key features of human PSCC.
• PSCC tumors exhibit an immunosuppressive microenvironment dominated by MDSCs.
• Combination therapy of immune checkpoint blockade with cabozantinib or celecoxib demonstrated synergistic efficacy.
• Pten deficiency was identified as a driver of cisplatin chemoresistance in this model.
• Drug screening and proteomics identified potential therapeutic avenues for PSCC.

Conclusions:

• The genetically engineered mouse model serves as a valuable resource for PSCC research.
• Targeting the immunosuppressive tumor microenvironment, particularly MDSCs, is a promising therapeutic strategy for PSCC.
• Understanding chemoresistance mechanisms is critical for developing effective PSCC treatments.
• This study provides essential tools and insights for advancing PSCC biology and therapy development.